[{"orgOrder":0,"company":"Sciwind","sponsor":"LYFE Capital","pharmaFlowCategory":"D","amount":"$37.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sciwind Biosciences Secures US$37 Million Series B Financing","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I"},{"orgOrder":0,"company":"Sciwind","sponsor":"Novotech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sciwind's Investigational New Drug Approved for NASH Trial","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I"},{"orgOrder":0,"company":"Sciwind","sponsor":"IDG Capital","pharmaFlowCategory":"D","amount":"$70.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sciwind Biosciences Completes $70 Million Series C Financing and Expands Leadership Team to Advance Metabolic Disease Pipeline","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical"},{"orgOrder":0,"company":"Sciwind","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sciwind Biosciences Acquires Global, Exclusive Rights to Develop and Commercialize Sanofi's GIP Receptor Agonists for the Treatment of Metabolic Disease","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical"},{"orgOrder":0,"company":"Sciwind","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sciwind Biosciences Completes Enrollment in Phase 2 Clinical Trial of XW003 in Type 2 Diabetes Patients","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II"},{"orgOrder":0,"company":"Sciwind","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sciwind Biosciences Announces Initiation of Dosing in Phase 1 Clinical Trial Evaluating XW004, an oral tablet formulation of its Proprietary GLP-1 Analogue (Ecnoglutide)","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I"},{"orgOrder":0,"company":"Sciwind","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sciwind Biosciences to Present Data from its GLP-1 and GIP Receptor Agonist Programs at The International Liver Congress(TM) EASL 2022","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical"},{"orgOrder":0,"company":"Sciwind","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sciwind Biosciences Announces Positive Topline Results from 20-week Phase 2 Clinical Trial of XW003 (Ecnoglutide), a novel long-lasting GLP-1 analogue, in Adult Patients with Type 2 Diabetes in China","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II"},{"orgOrder":0,"company":"Sciwind","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sciwind Biosciences Reports Positive Interim Results from Phase 1c\/2a Clinical Trial of XW003 (Ecnoglutide) in Overweight and Obese Adult Volunteers in China","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II"},{"orgOrder":0,"company":"Sciwind","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sciwind Biosciences Announces Initiation of Dosing in Phase 1 Clinical Trial Evaluating XW014, an Oral Small Molecule GLP-1 Receptor Agonist for the Treatment of Obesity and Type 2 Diabetes","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I"},{"orgOrder":0,"company":"Sciwind","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sciwind Biosciences Announces Positive Interim Results from Ongoing Phase 2b Clinical Trial of XW003 (ecnoglutide) in Patients with Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II"},{"orgOrder":0,"company":"Sciwind","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sciwind Biosciences Announces Initiation of Patient Dosing in Phase 3 Clinical Trials of Ecnoglutide (XW003), a Long-acting GLP-1 analog, for the Treatment of Type 2 Diabetes in China","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III"},{"orgOrder":0,"company":"Sciwind","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sciwind Biosciences Announces Positive Topline Results from Phase 3 Clinical Trial of Ecnoglutide (XW003), a Long-acting cAMP Signaling Biased GLP-1 Analog, in Adult Patients with Type 2 Diabetes in China","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III"},{"orgOrder":0,"company":"Sciwind","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sciwind Biosciences Announces Positive Results from Phase 1 Clinical Trial of XW004, an Oral Formulation of Long-acting GLP-1 Analog Ecnoglutide","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I"}]
Find Clinical Drug Pipeline Developments & Deals by Sciwind
XW004 (ecnoglutide) is a long-acting, cAMP signaling biased, glucagon-like peptide-1 (GLP-1) analog. It is under phase 1 clinical development for the treatment of type 2 diabetes and obesity.
XW003 (ecnoglutide) is a novel, cAMP signaling biased, long-acting GLP-1 analogue optimized for improved biological activity. It is under phase 3 clinical development for the treatment of Adult Patients with Type 2 Diabetes.
XW003 (ecnoglutide) is a novel, biased long-acting GLP-1 peptide analogue optimized for improved biological activity. GLP-1 analogs are effective therapies in managing type 2 diabetes, obesity, and have demonstrated clinical potential as a treatment for NASH.
XW003 is a novel, biased long-lasting GLP-1 peptide analogue optimized for improved biological activity and once weekly dosing. GLP-1 analogs are effective tools in managing type 2 diabetes, obesity, and have demonstrated clinical potential as a treatment for NASH.
XW014, a novel oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist in development for the treatment of obesity and type 2 diabetes. XW014 is easier to manufacture than GLP-1 peptide drugs and readily bioavailable after oral dosing.
After 14 weeks of treatment, participants receiving 1.8 mg and 2.4 mg XW003 (ecnoglutide) achieved statistically significant mean body weight loss of 8.32 kg (9.6%) and 7.27 kg (9.0%), respectively, compared to 0.62 kg (0.9%) for those receiving placebo (P<0.0001).
At week 20, participants receiving 0.4 mg, 0.8 mg, and 1.2 mg XW003 (ecnoglutide) had statistically significant HbA1c reductions from baseline of 1.8%, 1.9% and 2.4%, respectively, compared to 0.5% in participants receiving placebo (P < 0.0001).
XW003 is a novel, biased long-lasting GLP-1 peptide analog optimized for improved biological activity, cost-effective manufacturing, and once weekly dosing.
XW004 is an oral tablet formulation of Ecnoglutide, a novel long-lasting GLP-1 peptide analogue under development for the treatment of obesity, type 2 diabetes and NASH.
Company announced the completion of patient enrollment in Phase 2 trial of XW003 a novel, long-lasting GLP-1 peptide analog optimized for improved biological activity, cost-effective manufacturing, and once weekly dosing.
Market Place
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
